Skip to main content

Home/ Dr. Goodyear/ Group items tagged repurposed drugs

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

Overcoming cancer therapeutic bottleneck by drug repurposing | Signal Transduction and ... - 0 views

www.nature.com/...s41392-020-00213-8

cancer repurposed drugs

shared by Nathan Goodyear on 05 Jul 20 - No Cached
  • Nathan Goodyear on 05 Jul 20
     
    Great review article on the the repurpose of old drugs for modern cancer treatment.
Nathan Goodyear

Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer ... - 0 views

www.ncbi.nlm.nih.gov/...PMC5718030

chloroquine hydroxychloroquine cancer repurposed drugs

shared by Nathan Goodyear on 03 May 21 - No Cached
  • HCQ, doses for long-term use range between 200 and 400 mg per day.
  • Short-term administration of CQ or HCQ rarely causes severe side effects
  • Short-term administration of CQ or HCQ rarely causes severe side effects
  • ...24 more annotations...
  • bone marrow suppression
  • cardiomyopathy
  • irreversible retinal toxicity
  • hypoglycaemia
  • daily doses up to 400 mg of HCQ or 250 mg CQ for several years are considered to carry an acceptable risk for CQ-induced retinopathies, with the exception of individuals of short stature
  • chronic CQ or HCQ therapy be monitored through regular ophthalmic examinations (3–6 month intervals), full blood counts and blood glucose level checks
  • long-term HCQ exposure, skeletal muscle function and tendon reflexes should be monitored for weakness
  • both CQ and HCQ, specific caution is advised in patients suffering from impaired hepatic function (especially when associated with cirrhosis), porphyria, renal disease, epilepsy, psoriasis, glucose-6-phosphate dehydrogenase deficiency and known hypersensitivity to 4-aminoquinoline compounds
  • CQ and HCQ can effectively increase the efficacy of various anti-cancer drugs
  • CQ can prevent the entrapment of protonated chemotherapeutic drugs by buffering the extracellular tumour environment and intracellular acidic spaces
  • This study recommends an adjuvant HCQ dose of 600 mg, twice daily.
  • HCQ addition was shown to produce metabolic stress in the tumours
  • HCQ (400 mg/day)
  • important effects of CQ and HCQ on the tumour microenvironment
  • The main and most studied anti-cancer effect of CQ and HCQ is the inhibition of autophagy
  • the expression levels of TLR9 are higher in hepatocellular carcinoma, oesophageal, lung, breast, gastric and prostate cancer cells as compared with adjacent noncancerous cells, and high expression is often linked with poor prognosis
  • TLR9-mediated activation of the NF-κB signalling pathway and the associated enhanced expression of matrix metalloproteinase-2 (MMP-2), MMP-7 and cyclo-oxygenase 2 mRNA
  • HCQ can activate caspase-3 and modulate the Bcl-2/Bax ratio inducing apoptosis in CLL, B-cell CLL and glioblastoma cells
  • In triple-negative breast cancer, CQ was shown to eliminate cancer stem cells through reduction of the expression of Janus-activated kinase 2 and DNA methyl transferase 1 [106] or through induction of mitochondrial dysfunction, subsequently causing oxidative DNA damage and impaired repair of double-stranded DNA breaks
  • CQ or HCQ would be considered for use in combination with immunomodulation anti-cancer therapies
  • Therapies used in combination with CQ or HCQ include chemotherapeutic drugs, tyrosine kinase inhibitors, various monoclonal antibodies, hormone therapies and radiotherapy
  • Most studies hypothesise that CQ and HCQ could increase the efficacy of other anti-cancer drugs by blocking pro-survival autophagy.
  • daily doses between 400 and 1200 mg for HCQ are safe and well tolerated, but two studies identified 600-mg HCQ daily as the MTD
  • HCQ is often administered twice daily to limit plasma fluctuations and toxicity
Nathan Goodyear

The Repurposing Drugs in Oncology (ReDO) Project - 0 views

www.ncbi.nlm.nih.gov/...PMC4096030

ReDO project cancer oncology drugs

shared by Nathan Goodyear on 19 May 18 - No Cached
  • Nathan Goodyear on 19 May 18
     
    Repurposing old drugs for the new fight in cancer.
Nathan Goodyear

Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent - 0 views

www.ncbi.nlm.nih.gov/...PMC4096024

Mebendazole cancer

shared by Nathan Goodyear on 13 Aug 19 - No Cached
  • Nathan Goodyear on 13 Aug 19
     
    Another repurposed anti-parasite drug in the treatment of cancer.
Nathan Goodyear

A conceptually new treatment approach for relapsed glioblastoma: Coordinated underminin... - 0 views

www.ncbi.nlm.nih.gov/...PMC3720600

repurposed medications cancer repurposed drugs

shared by Nathan Goodyear on 23 Oct 23 - No Cached
  • Nathan Goodyear on 23 Oct 23
     
    first publication that I can find.
Nathan Goodyear

Phosphodiesterase 5 Inhibitors Enhance Chemotherapy Killing in Gastrointestinal/Genitou... - 0 views

www.ncbi.nlm.nih.gov/...PMC3935155

chemotherapy phosphodiesterase 5 inhibitors repurposed drugs PDE inhibitors PDE5I phosphodiesterase inhibitors cancer PDE5 inhibitors

shared by Nathan Goodyear on 08 Mar 21 - No Cached
  • Nathan Goodyear on 08 Mar 21
     
    PDE inhibitors repurposed to augment chemotherapy in treatment of cancer.
Nathan Goodyear

Repurposing Drugs in Oncology (ReDO)-mebendazole as an anti-cancer agent. ecancermedica... - 0 views

ecancer.org/...le-as-an-anti-cancer-agent.php

Mebendazole cancer

shared by Nathan Goodyear on 13 Aug 19 - No Cached
  • Nathan Goodyear on 13 Aug 19
     
    Good read on mebendazole's effect in a variety of cancer types.
1 - 20 of 37 Next ›
Showing 20▼ items per page